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Summary: The effect of deep barbiturate anesthesia on brain
glucose transport, TCA cycle flux, and aspartate, glutamate,
and glutamine metabolism was assessed in the rat brain in vivo
using 13C nuclear magnetic resonance spectroscopy at 9.4 T in
conjunction with [1-13C] glucose infusions. Brain glucose con-
centrations were elevated, consistent with a twofold reduced
cerebral metabolic rate for glucose (CMRglc) compared with
light -chloralose anesthesia. Using a mathematical model of
neurotransmitter metabolism, several metabolic reaction rates
were extracted from the rate of label incorporation. Total oxi-
dative glucose metabolism, CMRglc(ox), was 0.33 ± 0.03
mol·g−1 · min−1. The neuronal TCA cycle rate was similar to
that in the glia, 0.35 ± 0.03 mol · g−1 · min−1 and 0.26 ± 0.06
mol · g−1 · min−1, respectively, suggesting that neuronal en-
ergy metabolism was mainly affected. The rate of pyruvate
carboxylation was 0.03 ± 0.01 mol·g−1 · min−1. The exchange
rate between cytosolic glutamate and mitochondrial 2-oxoglu-
tarate, Vx, was equal to the rate of neuronal pyruvate dehydro-
genase flux. This indicates that Vx is coupled to CMRglc(ox),
implying that the malate-aspartate shuttle is the major mecha-
nism that facilitates label exchange across the inner mitochon-
drial membrane. The apparent rate of glutamatergic neurotrans-
mission, VNT, was 0.04 ± 0.01 mol·g−1 · min−1, consistent
with strong reductions in electrical activity. However, the rates
of cerebral oxidative glucose metabolism and glutamatergic
neurotransmission, CMRglc(ox)/VNT, did not correlate with a
1:1 stoichiometry. Key Words: NMR—Glutamate neurotrans-
mission—Pentobarbital—Energy metabolism—Glucose trans-
port.
Glucose is the major fuel required to maintain normal
brain function. At rest, the brain accounts for a major
fraction of the body’s oxidative glucose consumption
even though the brain accounts only for a fraction of
body mass. The brain thus has a high glucose metabolic
activity, which is known to be modulated by brain func-
tion (Magistretti, 1999). In addition, a number of anes-
thetics can affect the rate of cerebral glucose metabolism.
Of these, barbiturates can have a profound effect on brain
function; they are known to depress cerebral glucose
utilization and electrical activity (Hodes et al., 1985;
Nilsson and Siesjo, 1975; Sokoloff et al., 1977; Strang
and Bachelard, 1973).
Barbiturates are known to depress metabolism by in-
hibiting the oxidation of NADH in the respiratory chain
(Aldridge and Parker, 1960; Chance and Hollunger,
1963). In cell cultures, barbiturates have been shown to
reduce neuronal glutamate release and to inhibit astro-
cytic glutamate uptake (Qu et al., 1999; Swanson and
Seid, 1998). Most studies suggest that barbiturates have
an effect on both glial and neuronal cells, although de-
pression of oxygen uptake and CO2 production from glu-
cose has been more profound in neuronal cell cultures
than in astrocyte cell cultures (Hertz et al., 1986; Yu et
al., 1983).
Barbiturates can induce a near complete depression of
the electrical activity in the brain (Contreras et al., 1999;
Yamazaki et al., 1994) and glutamatergic neurotransmis-
sion can be greatly reduced under such conditions. Glu-
tamatergic action occurs by neuronal release of gluta-
mate into the synaptic cleft, interaction with postsynaptic
receptors, and elimination of glutamate from the synaptic
cleft by uptake into neighboring cells, and uptake into
astrocytes is the dominant if not exclusive process
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(Bergles and Jahr, 1998; Danbolt, 2001). To maintain the
nerve terminal glutamate concentration, the glutamate
taken up by the astrocytes is converted to glutamine,
which is electrophysiologically inactive, and then trans-
ported to the neuron and converted back to glutamate to
be packaged into vesicles ready for renewed release.
Hence, the cycling of carbon between the large neuronal
pool of glutamate and the large glial pool of glutamine
can be indicative of the rate of glutamatergic action.
Using 13C nuclear magnetic resonance (NMR) spec-
troscopy, label incorporation into glutamate and gluta-
mine can be measured in vivo (Gruetter et al., 1994;
Sonnewald et al., 1997) and cerebral compartmentation
can be assessed noninvasively (Gruetter et al., 1994,
2001; Shen et al., 1999; Sibson et al., 1998). We sought
to assess the rates of cerebral metabolism in deep pen-
tobarbital anesthesia in the intact rat brain in vivo. Under
conditions of greatly depressed electrophysiologic activ-
ity, we expect the label transfer from glutamine to glu-
tamate to be nearly completely suppressed. Previously,
the condition of deep pentobarbital anesthesia was stud-
ied in vivo using 13C NMR spectroscopy by measuring
label incorporation into the glutamate C4 and glutamine
C4 positions only, and it was assumed that isoelectricity
results in zero transfer of glutamate from neurons to glia
(Sibson et al., 1998). The measurement of more label
incorporation curves reduces the number of constraints
and assumptions made in the modeling (Gruetter et al.,
2001). To interpret labeling of glutamate and glutamine,
the compartmentation of cerebral energy metabolism
into at least a neuronal and a glial compartment is
needed, and the metabolism in these two compartments
needs to be distinguished from glutamatergic action.
In the present study, we have extended our previous
methodology and modeling to the deeply anesthetized rat
brain to assess the rate of several key fluxes simulta-
neously. In addition, we have combined this measure-
ment for the first time with the direct measurement of
cerebral glucose concentrations, which permits insight
into the degree of depression on net glucose uptake into
the brain. According to the finding by Sibson et al.
(1998), oxidative glucose metabolism was close to zero
at isoelectricity in the brain, and thus the concentration of
brain glucose (on a per milliliter brain water basis) is
expected to be close to that in plasma, given the nature of
the glucose transport process by facilitated diffusion
(Gjedde, 1992). Finally, we assessed the exchange rate
between the mitochondrial TCA cycle intermediate
2-oxoglutarate and the cytosolic amino acid glutamate,
Vx, under conditions of extremely depressed cerebral
metabolism. We previously reported that Vx is on the
order of the flux through pyruvate dehydrogenase, VPDH
(Gruetter et al., 2001). Since oxidative glucose consump-
tion in the brain is largely through pyruvate dehydroge-
nase, the reducing equivalents produced in glycolysis
must be oxidized. Under normoxic conditions, the reduc-
ing equivalents are transported into the mitochondrion by
several shuttles. Of these shuttles, the malate-aspartate
shuttle is believed to be the most active in the brain. The
exchange of carbon between mitochondrial 2-oxogluta-
rate and cytosolic glutamate occurs as an integral part of
the malate-aspartate shuttle. Provided that the malate-
aspartate shuttle is a major contributor to Vx, this ex-
change rate can depend on the rate of oxidative glucose
consumption, CMRglc(ox), and thus affect the calculated
metabolic rates, that is, VPDH, from glutamate turnover
curves. All previous modeling of cerebral energy me-
tabolism in the living rat brain, however, was done under
the assumption that this exchange rate, Vx, is very fast
compared with VPDH and that the net transport of reduc-
ing equivalents by the malate-aspartate shuttle is only a
minor contributor to Vx. This assumption was made
based on modeling of data from a single study, which
was conducted in the awake, paralyzed rat (Mason et al.,
1992). Based on our previous findings in the human
brain (Gruetter et al., 2001), we expected Vx to vary in
conjunction with changes in the flux through the pyru-
vate dehydrogenase complex in different metabolic con-
ditions. Thus, this study is also the first to evaluate
whether the exchange rate, Vx, indeed varies under con-
ditions of greatly depressed cerebral metabolism.
MATERIALS AND METHODS
Animal preparation
The study was performed according to the guidelines for the
care and use of laboratory animals at the University of Minne-
sota and was approved by the Institutional Animal Care and
Use Committee (IACUC). Male Sprague-Dawley rats (n  5,
246 ± 21 g, mean ± SD) were fasted overnight with access to
water before studies. Animals were anesthetized using 2% iso-
flurane (Marsam Pharmaceuticals, Cherry Hill, NJ, U.S.A.) in
a 1:1 mixture of nitrous oxide (N2O) and oxygen (O2) gases for
surgery. The animals were then intubated and ventilated with a
pressure-driven ventilator (Kent Scientific, Litchfield, CT,
U.S.A.). End tidal CO2 was monitored during surgery and ex-
periments with a capnometer (SC-300; BCI International,
Waukesha, WI, U.S.A.). Catheters were inserted into both
femoral arteries for blood gases and glucose analyses, and
monitoring of arterial blood pressure, and also inserted into
both femoral veins for intravenous infusion of pentobarbital
and glucose. Arterial blood pressure and respiratory rate and
pattern were continuously monitored with a multitrace recorder
(AcqKnowledge, Biopak, CA, U.S.A.).
Right after surgery, anesthesia was switched to pentobarbital
solution (10 mg/mL; Abbott Laboratories, North Chicago, IL,
U.S.A.) administered intravenously (80 mg · kg−1 · h−1) to in-
duce an isoelectric deep anesthesia state according to a previ-
ous report (Contreras et al., 1999). The animals were secured
using a home-built Delrin holder with a bite bar and two ear-
inserts to provide a fixed position of the skull. The animal was
then placed in an acrylic holder attached to an insert in the gradient
coil to ensure stability of the experimental setup during experi-
ments. Body temperature was maintained at 37.0 ± 0.5°C with a
warm water circulation system based on a feedback obtained
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from a rectal temperature probe (Cole Palmer, Vernon Hills, IL,
U.S.A.).
Ninety-nine percent-enriched [1-13C] D-glucose (20% wt/vol
solution; Isotec Inc., Miamisburg, OH, U.S.A.) was infused
into the left femoral vein according to a previously described
protocol to achieve rapid 13C enrichment of plasma glucose
(Choi et al., 1999). In brief, the glucose infusion protocol was
as follows: After an initial infusion rate of 1.30 g · kg body
wt−1 · min−1 for 6 seconds and 0.26 g · kg body wt−1 · min−1
for 30 seconds, infusion rates were dropped in an exponentially
decaying fashion over 16 minutes. Subsequently, the infusion
rate of glucose (0.024 to 0.030 g · kg body wt−1 · min−1) was
adjusted based on continuous monitoring of the NMR signals
of brain glucose and the concomitantly measured plasma glu-
cose concentrations to achieve stable target glycemic levels. At
the end of amino acid turnover study, the infusion rate of glu-
cose was increased in a stepwise fashion to achieve new steady-
state target glycemia for the measurement of glucose transport
kinetics. Arterial blood was withdrawn from the femoral artery
through a Teflon-tubing line (Spectrum Chromatography,
Houston, TX, U.S.A.) for blood gas analysis (PCO2, PO2) and
glucose measurements. Blood was immediately centrifuged af-
ter sampling, and plasma glucose concentrations were mea-
sured using a hexokinase method (Sigma, St. Louis, MO,
U.S.A.). The concentration of whole blood glucose was also
measured using a glucose oxidase method (Roche Diagnostics,
Indianapolis, IN, U.S.A.) and calibrated against the plasma
glucose measurements. Physiologic parameters were adjusted
and maintained within normal ranges throughout experiments.
Nuclear magnetic resonance methods
All experiments were performed on a 9.4-T, 31-cm-bore
horizontal magnet (Magnex Scientific, Abingdon, U.K.), inter-
faced to a Varian INOVA console (Varian, Palo Alto, CA,
U.S.A.). An actively shielded gradient coil (Magnex Scientific,
Abingdon, U.K.) with an 11-cm inner diameter was used,
which was capable of switching 300 mT/m in 500 s. A qua-
drature 1H surface RF coil (14-mm diameter) and a linear three-
turn 13C coil (12-mm diameter) was used as a transceiver for
1H MRI and 13C NMR (Adriany and Gruetter, 1997). A 99%
13C-enriched formic acid sphere was located at the center of the
linear coil as an external reference, and the coil was placed on
the animal’s head directly over the brain. The position of the
brain was identified by T1-weighted images acquired using a
fast low-angle shot sequence (repetition time [TR]  10 ms,
echo time  5 ms). The volume of interest (VOI) was placed
in the brain and a nominal 510-L volume was the typical size
of VOI. Three-dimensional localization based on outer volume
saturation was used to ensure complete elimination of signals
from extracerebral tissues as demonstrated previously (Choi et
al., 1999, 2000). The efficiency of localization was verified
from the absence of the natural abundance lipid signal (30.5
ppm) in spectra optimized for the amino acid region (20 to 40
ppm) because the lipid signals are not detectable in the normal
brain. The localized signals (64 scans) of glycogen and glucose
were acquired with spectrometer offset set to 100 ppm (TR
1 second) and interleaved with acquisition of localized signals
(64 scans) from the amino acid region with spectrometer offset
set to 30.5 ppm (TR 1.5 second) to minimize chemical shift
displacement errors.
The 13C-labeled glutamate, glycogen, and glucose reso-
nances were quantified using the external reference method as
described previously (Choi et al., 1999; Gruetter et al., 1998b).
In short, in vivo 13C NMR signals were quantified by compari-
son with the measurements of solutions containing 250 mmol/L
glutamate, ∼400 mmol/L natural abundance oyster glycogen
and 0.9 mmol/L of 99%-enriched [1-13C] D-glucose. The ex-
ternal reference measurements were performed under identical
experimental conditions as in vivo. The corrections of coil-
loading effect on sensitivity were assessed by measuring the
pulse duration of 180° for a square pulse applied to the signals
of the 13C formic acid, which is placed at the center of the 13C
coil. The nuclear Overhauser effect (NOE) and T1 effects were
corrected by measuring the saturation factors from the 13C
signals with a TR of 7.5 seconds without NOE generation,
which is more than fivefold longer than the T1 of the metabo-
lites (Choi et al., 2000).
Spectra were analyzed using the peak-fitting algorithm sup-
plied by the spectrometer software. To reduce variability, peak
line widths of 13C-13C doublets were set to that of the corre-
sponding center peak, and the frequencies of the 13C-13C dou-
blets were set relative to the main resonance in spectra based on
their relative position determined in spectra summed for 1 hour
at isotopic steady state. Concentrations of 13C label, e.g.,
13Glu4, were calculated from the area of the fitted peaks, in-
cluding the doublets. The residual was visually inspected to
verify proper convergence of the peak fitting routine.
Isotopic enrichment was measured in spectra following sum-
mation of 32 spectra acquired toward the end of the study at
isotopic steady-state using isotope isomer (isotopomer) analy-
sis (Jeffrey et al., 1999). Since those glutamate molecules la-
beled at C4 that have a C3 labeled as well are represented by
the doublet at glutamate C4, that is [3,4-13C2]Glu, the isotopic
enrichment of glutamate C3 is given by the relative amount
of doubly labeled glutamate C4, i.e., IE(13Glu3) 
[3,4-13C2]Glu/13Glu4. Likewise, the isotopic enrichment of
glutamate C4 can then be calculated from the relative amount
of 13C incorporated into glutamate C4 and the isotopic enrich-
ment of glutamate C3, as follows: IE(13Glu4)  IE(13Glu3)
13Glu4/13Glu3. The same pertinent equations hold true for the
glutamine C3 and C4, respectively. From the quantification of
the amount of 13C label incorporated and the isotopic enrich-
ment at the given position, the total pool size of glutamate and
glutamine was calculated.
Modeling 13C label turnover curves
We used a recently described mathematical model of com-
partmentalized neurotransmitter metabolism (Gruetter et al.,
2001) to derive the following metabolic rates: neuronal TCA
cycle flux, VPDH; glial TCA cycle flux, Vg; glial rate of pyru-
vate carboxylation, VPC; exchange between (mitochondrial)
2-oxoglutarate and (cytosolic) glutamate, Vx; label dilution,
Vout; and the apparent rate of glutamate neurotransmission
(glutamine-glutamate cycle rate), VNT. From these metabolic
rates, the following rates were calculated: glial glutamine
synthetase flux, Vsyn; total oxidative glucose consumption,
CMRglc(ox); and the rate of ATP synthesis from glucose in neu-
rons and glia. For a graphical representation of the model, see Fig.
5 in (Gruetter et al., 1998a) and Fig. 1 in (Gruetter et al., 2001).
For the modeling, the measured pool sizes in Table 1 were
TABLE 1. Quantification of cerebral amino acid pools
using an isotopomer analysis to determine isotopic
enrichment and quantified amount of 13C label
Glu4 Glu3 Gln4 Gln3 Asp3
Pool size
(mol/g)
9.4 ± 0.9 9.2 ± 0.4 6.0 ± 1.2 5.7 ± 1.8 1.5 ± 0.15
Values are mean ± SD (n  5).
Glu, glutamate; Gln, glutamine; Asp, aspartate.
COMPARTMENTALIZED CEREBRAL METABOLISM IN VIVO 1345
J Cereb Blood Flow Metab, Vol. 22, No. 11, 2002
used. Brain glucose isotopic enrichment was assumed to have
a half-life of 5 min and the following time courses were fitted:
13Glu4(t), 13Gln4(t), 13Glu3(t), 13Gln3(t), 13Asp3(t) using
graphical fitting software (SAAM II, The SAAM Institute, Se-
attle, WA), which provides an error analysis (SD of the fitted
parameter, from which the 95% confidence interval can be
calculated) as well as a covariance analysis.
Modeling glucose transport kinetics
The steady-state measurement of brain glucose transport ki-
netics was analyzed using the reversible model of glucose
transport kinetics (Cunningham et al., 1986) using procedures
and equations previously described (Choi et al., 2001; Gruetter
et al., 1998b). For the fitting, we assumed the apparent Michae-
lis-Menten constant Kt to be the same as in light -chloralose
anesthesia, namely, 3.3 mmol/L (Choi et al., 2001) and the
model parameter Tmax/CMRglc was fitted using Eq. 4 in Gruet-
ter et al. (1998b), where Tmax represents the apparent maximal
rate of glucose transport across the blood–brain barrier.
RESULTS
The simultaneous measurement of the brain glucose
concentration at different plasma glucose concentrations
allowed an assessment of cerebral glucose transport ki-
netics at steady state. During deep pentobarbital anesthe-
sia, the brain glucose concentration was clearly higher
than what we previously reported in the lightly -chlo-
ralose anesthetized rats (Choi et al., 2001), as shown in
Fig. 1. Note that although the brain glucose concentra-
tion was substantially higher, it was still considerably
lower than the plasma glucose concentration, which im-
plies that brain glucose consumption was still substantial.
The reversible Michaelis-Menten model of glucose
transport was used to fit the data as in our previous
studies (Choi et al., 2001; Seaquist et al., 2001; Gruetter
et al., 1998b) and yielded a ratio of maximal transport
rate to cerebral glucose consumption rate, Tmax/CMRglc
of 5.0 ± 0.24. This ratio was approximately twofold
higher than that in the -chloralose anesthetized rats
(Choi et al., 2001). In these calculations, we assumed
that Kt (3.3. mmol/L) was constant between -chloralose
and pentobarbital anesthetized rats. Even when assuming
that Kt varied by up to fivefold, however, the calculated
Tmax/CMRglc did not vary by more than ±10%. This
result indicates that net glucose uptake by the brain was
only reduced by 50%.
Simultaneous measurement of brain glycogen concen-
trations indicated that brain glycogen C1 reached con-
centrations of 8.2 ± 2.7 mol/g (mean ± SD, n 3) after
7 hours of [1-13C] glucose infusion. A time course of the
brain glycogen C1 signal and concomitant quantification
of 13C label are shown in Fig. 2. The measurement of
brain glucose and glycogen signals alternated in an in-
terleaved fashion with measurements optimized for the
spectral region containing signals from neurotransmitters
and amino acids such as glutamate, glutamine, -amino-
butyric acid, and aspartate. The turnover curves of glu-
tamate, glutamine, and aspartate were used to extract a
number of metabolic fluxes based on a recently de-
scribed mathematical model of compartmentalized neu-
rotransmitter metabolism (Gruetter et al., 2001).
Label incorporation into the glutamate C4, 13Glu4,
glutamate C3, 13Glu3, glutamine C4, 13Gln4, glutamine
C3, 13Gln3, and aspartate C3 resonances, 13Asp3, was
readily observed (Fig. 3). During pentobarbital anesthe-
sia, optimized infusion of 99%-enriched [1-13C] glucose
resulted in a rapid initial rise in plasma glucose and a
concomitant stable brain glucose C1 signal (Fig. 4A).
Isotopic steady state in the amino acid pools was
achieved after several hours, consistent with depressed
metabolism (Fig. 3). The spectra demonstrated the re-
solved detection of 13C-13C isotopomers as in previous
studies (Choi et al., 2000; Gruetter et al., 1994, 2001).
The isotopic enrichment of glutamate C3 was calculated
from the isotopomers within glutamate as described in
Materials and Methods and similarly for glutamine: at
348 ± 21 min into the infusion, the isotopic enrichment
of 13Glu3 was IE(13Glu3)  0.29 ± 0.03 and of 13Gln3,
IE(13Gln3)  0.20 ± 0.04 (mean ± SD , n  5). The
isotopic enrichment of 13Glu4 was IE(13Glu4)  0.31 ±
0.03 and IE(13Gln4) 0.21 ± 0.05. The similarity of the
isotopic enrichment of C3 and of C4 in both glutamate
and glutamine indicates that both glutamate and gluta-
mine were completely turned over at this late time point.
From the quantified amount of 13C label in C3 and C4,
the total pool size of glutamate, glutamine, and aspartate
was calculated assuming the same isotopic enrichment of
aspartate and glutamate (Table 1). The measured time
courses of label incorporation (Fig. 4C) using a math-
ematical model of compartmentalized neurotransmitter
FIG. 1. Quantification of brain glucose concentration as a func-
tion of plasma glucose in rats anesthetized with pentobarbital
(). The solid line is the best fit of the reversible Michaelis-
Menten model of glucose transport using Eq. 3 in Choi et al.
(2001) to the data, assuming a fixed Kt of 3.3 mmol/L as previ-
ously reported. For comparison, the measurement of brain glu-
cose in the lightly -chloralose anesthetized rat (; 24
mg · kg−1 · h−1) is reproduced from Choi et al. (2001), and the
dotted line indicates the best fit of the glucose transport model.
CMRglc, cerebral metabolic rate of glucose.
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metabolism (Gruetter et al., 2001) yielded several meta-
bolic rates (Table 2).
Clearly, the rate of label incorporation into 13Glu4 was
paralleled by a label increase in 13Glu3 and 13Gln4, the
latter indicating active metabolism in glia (Fig. 4C). Al-
though the labeling of 13Glu3 relative to 13Glu4 was
slower, there was no discernible lag as would be ex-
pected if the glutamate pool were turned over completely
before the label continues to the next turn of the TCA
cycle (Fig. 4B). To further demonstrate that our data are
incompatible with a fast Vx (Mason et al., 1992) and that
Vx was rather on the order of the rate of the TCA cycle,
VPDH, we fitted VPDH and Vout to the 13Glu4(t) and
13Gln4(t) data, assuming Vx was 57 mol · g−1 · min−1,
as was done in previous studies (Sibson et al., 1998),
while keeping the other fluxes at the values shown in row
1 of Table 2 (dashed line in Fig. 4B). The resulting VPDH
was 0.14 ± 0.02 mol · g−1 · min−1. However, the calcu-
lated 13C label in glutamate C3 relative to that in C4,
13Glu3/13Glu4 is clearly less consistent with the experi-
mentally measured 13Glu3/13Glu4 compared to the mod-
eling done in this study as indicated by the solid line in
Fig. 4B. It is noteworthy that the observation Vx∼VPDH
did not depend on the assumed intercellular distribution
of glutamate (Table 3).
The exchange rate between 2-oxoglutarate and gluta-
mate, Vx, was very slow and constrained by the lower
boundary afforded by the model, VPDH. Removing this
constraint resulted in Vx < VPDH (second row in Table 2)
and resulted in an increase of CMRglc(ox) because of the
covariance of Vx and VPDH. In either case, the apparent
rate of glutamatergic neurotransmission, VNT, was con-
sistently close to zero (Table 2), consistent with reports
suggesting isoelectricity for this dose of pentobarbital
anesthesia (Contreras et al., 1999). However, the glial
TCA cycle flux, Vg, and the rate of anaplerosis, i.e., flux
through pyruvate carboxylase, VPC, were substantial. In
both cases presented in Table 2, the modeling results in
approximately half of the total ATP production or energy
consumption being in the neuronal compartment.
DISCUSSION
This study is the first localized 13C NMR study to
assess total glucose consumption changes and to measure
the apparent rate of glutamatergic action under deep pen-
tobarbital anesthesia. It is also the first simultaneous
measurement and modeling of cerebral glucose content,
FIG. 3. Observation of label incorporation into multiple positions
of glutamate (Glu), glutamine (Gln), and aspartate (Asp). Time
scale from the start of [1-13C] glucose infusion is shown on the
right side. Each 13C magnetic resonance imaging spectrum in
vivo in the stack plot is shown with 25-minute temporal resolution,
8-Hz Gaussian resolution enhancement applied before zero-
filling and fast Fourier transformation. No baseline correction was
applied.
FIG. 2. (A) Observation of label incor-
poration into glycogen C1 (13Glyc1)
during intravenous infusion of [1-13C]
glucose. The 13C nuclear magnetic
resonance spectra shown in the stack
plot correspond to 25-minute temporal
resolution. Time scale from the start of
[1-13C] glucose infusion is shown on
the left side. Gaussian resolution en-
hancement (20 Hz) was applied be-
fore zero-filling and fast Fourier trans-
formation. No baseline correction was
applied. (B) Corresponding time
course of 13C-labeled brain glycogen
concentration.
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and label incorporation into multiple positions in amino
acids and neurotransmitters such as glutamate, gluta-
mine, and aspartate. The increased information content
achieved in this study allowed a robust assessment of
cerebral metabolic rates in the glial and the neuronal
compartments.
For example, the exchange between mitochondrial
2-oxoglutarate and cytosolic glutamate, Vx, involves
transport of charged acids across the heavily polarized
inner mitochondrial membrane and is achievable only
through transporters (LaNoue and Tischler, 1974). Vx
being on the order of the neuronal TCA cycle rate, VPDH
(Table 2) implies that the malate-aspartate shuttle is the
major mechanism in the deeply anesthetized rat brain,
assuming that the glycerol-phosphate shuttle is a minor
contributor to the flux of reducing equivalents from the
cytosol into the mitochondria. Together these results also
show that this exchange can depend on the metabolic
activity of the cell. This is in agreement with measure-
ments in the perfused heart, where the exchange rate was
found to be on the order of the TCA cycle rate (Yu et al.,
1997). Studies have suggested that the other major
shuttle that transports reducing equivalents from the cy-
tosol to the mitochondrion, namely, the glycerol-
phosphate shuttle, may be active in the heart (Chatham et
al., 1995) and the liver (Poso, 1979). When assuming
that the glycerol-phosphate shuttle is also active in the
brain, the condition that Vx is larger than VPDH can be
eliminated from the fitting. In this case, Vx was indeed
lower than VPDH (Table 2), suggesting that fluxes
through shuttles other than the malate-aspartate shuttle
may not be negligible in the brain in vivo. It was re-
ported, however, that the degree of inhibition of trans-
aminase flux and, therefore, malate-aspartate shuttle ac-
tivity, was proportional to the degree of reduced oxygen
consumption in the brain (Fitzpatrick et al., 1983), sug-
gesting that very few reducing equivalents can be trans-
ported by other shuttle mechanisms. Removing the con-
straint Vx  VPDH has a strong effect on some of the
rates. Because of the known negative covariance of VPDH
and Vx, the increase in VPDH was not an unexpected
result.
The rate of label incorporation into glutamate, gluta-
mine, and aspartate was analyzed using a mathematical
model of compartmentalized neurotransmitter metabo-
lism. The derived metabolic rates provide further insight
into the action of pentobarbital and depressed electrical
activity on cerebral metabolism in neurons and glia. The
apparent rate of neurotransmission, VNT, was reduced to
very close to zero, 0.04 mol · g−1 · min−1, which im-
plies suppression of glutamatergic action, consistent with
almost complete isoelectricity. It is interesting to note
that under the present conditions, anaplerosis, although
quantitatively small, constitutes about half of the flux
through glutamine synthetase, Vsyn. Conversely, this
FIG. 4. (A) Time course of 13C-labeled brain glucose during in-
travenous infusion of [1-13C] glucose. (B) Comparison of label
incorporation into glutamate (Glu) C4 and C3. The solid line in-
dicates calculation using the parameters shown in row 1 of Table
2. The dashed line was calculated after fitting to the 13Glu4(t) and
13Gln4( t ) data only, which resul ted in VPDH = 0.15
µmol · g−1 · min−1 when assuming Vx = 57 µmol · g−1 · min−1 as in
Sibson et al. (1998). (C) Time course of label incorporation into
multiple positions of amino acids in the rat brain (13Glu4; 13Gln4[]; 13Glu3 []; 13Gln3 []; 13Asp3 []). The data represent mean
± SD of all five studies, and the solid lines represent the best fit
of the model to the data.
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means that glutamatergic action is not the dominant con-
tributor to glutamine synthesis. In this context, it was
intriguing to note that the rate of labeling for glutamine
C4, 13Gln4, apparently reached steady state as fast as the
glutamate C4, 13Glu4, as judged from the label incorpo-
ration shown in Figs. 3 and 4C. This is direct experi-
mental evidence for either a high metabolic rate in the
glial compartment relative to the neuronal compartment
or a very fast rate of label transfer from neuronal gluta-
mate to glial glutamine, VNT. Faster glutamatergic action
(represented by VNT) under deep anesthetic states com-
pared with states with higher electrical activity, however,
is very unlikely and would be inconsistent with the low
VNT.
Our results suggest that glial energy consumption is
quite considerable and amounts to approximately half of
the total ATP synthesis from glucose under deep pento-
barbital anesthesia. This is rather surprising when we
consider that it is generally assumed that most of the
oxidative glucose metabolism is in the neuronal compart-
ment, as we have observed, for instance, in the conscious
brain (Gruetter et al., 2001). Therefore, our current find-
ing of substantial glial energy metabolism implies a ma-
jor site of action for barbiturates in the neuronal com-
partment. In cell cultures, barbiturates have been shown
to depress neuronal metabolism more than in astrocytes
(Hertz et al., 1986). In addition, some studies have re-
ported increased deoxyglucose uptake in cultured astro-
cytes with increasing pentobarbital anesthesia (Swanson
and Seid, 1998). Barbiturates are thought to act on the
respiratory chain and the overall reduced oxygen con-
sumption (Blacklock et al., 1987; Donegan et al., 1985),
and thus likely reflects the larger effect of pentobarbital
on the neuronal compartment than the glial compartment
(Hertz et al., 1986; Yu et al., 1983).
In our study, the simultaneous measurement of brain
glucose content allowed an assessment of the effect of
pentobarbital on overall glucose metabolism. The con-
siderable gradient remaining between brain and plasma
glucose concentrations, as can be seen in Fig. 1, indicates
substantial glucose uptake during deep pentobarbital an-
esthesia. Modeling glucose transport indicates that
CMRglc was half of that in the light -chloralose anes-
thetized rat brain. In this analysis, it was assumed that the
apparent Michaelis-Menten constant for glucose trans-
port, Kt, and the maximal apparent glucose transport rate,
Tmax, were not affected by the deep pentobarbital anes-
thesia. A recent report suggested that the transport affin-
ity for glucose may change under pentobarbital anesthe-
sia in cultured cells and erythrocytes (Haspel et al.,
1999). When we allow a fivefold change in the apparent
Michaelis-Menten constant Kt (Kt ranging from 1 to 5
mmol/L), Tmax/CMRglc was affected by approximately
20%, which did not change the conclusions of this study,
namely, that overall glucose metabolism was still con-
siderable. If it is assumed that the twofold reduction in
glucose metabolic rate reflects mainly changes in the
neuronal energy metabolism, then we estimate that under
-chloralose anesthesia, glial energy metabolism repre-
sents only approximately 25% of total energy metabo-
lism as measured by labeling from glucose.
The decrease in cerebral metabolic rate under pento-
barbital anesthesia is substantially less than what has
been reported in an earlier study (Sibson et al., 1998),
TABLE 3. Effect of assumed intercellular distribution on derived metabolic fluxes (µmol  g−1  min−1) by fitting the model
(from Gruetter et al., 2001) to the time courses in Figure 4C
 VPDH Vx CMRglc(ox) VNT VPC Vg Vsyn
0.02 0.39 ± 0.03 0.39 ± 0.03 0.34 ± 0.03 0.05 ± 0.02 0.03 ± 0.01 0.23 ± 0.06 0.08 ± 0.01
0.05 0.37 ± 0.03 0.37 ± 0.03 0.35 ± 0.04 0.05 ± 0.02 0.03 ± 0.01 0.27 ± 0.07 0.08 ± 0.01
0.10 0.33 ± 0.03 0.33 ± 0.03 0.38 ± 0.05 0.03 ± 0.02 0.04 ± 0.01 0.35 ± 0.09 0.07 ± 0.01
0.16 0.29 ± 0.02 0.29 ± 0.02 0.53 ± 0.07 0.00 ± 0.00 0.07 ± 0.01 0.63 ± 0.13 0.07 ± 0.01
0.21 0.26 ± 0.02 0.26 ± 0.02 0.54 ± 0.06 0.00 ± 0.00 0.07 ± 0.01 0.68 ± 0.12 0.07 ± 0.01
Values are given as mean ± SE.  represents the fraction of total glutamate that was assumed to be in the glial compartment ( 0.05 was used
in Table 2).
VPDH, the flux through pyruvate dehydrogenase; Vx, the exchange rate between the mitochondrial TCA cycle intermediate 2-oxoglutarate and the
cytosolic amino acid glutamate; CMRglc(ox), the rate of oxidative glucose consumption; VNT, the apparent rate of glutamatergic neurotransmission;
VPC, the rate of pyruvate carboxylase; Vg, the glial TCA cycle flux; Vsyn, the flux through glutamine synthetase.
TABLE 2. Derived metabolic fluxes (µmol  g−1  min−1) by fitting the model (from Gruetter et al., 2001) to the time courses in
Figure 4C
Vx constraint VPDH Vx CMRglc(ox) VNT VPC Vg Vsyn
Vx  VPDH 0.35 ± 0.03 0.35 ± 0.03 0.33 ± 0.03 0.04 ± 0.01 0.03 ± 0.01 0.26 ± 0.06 0.07 ± 0.01
none 0.41 ± 0.05 0.22 ± 0.05 0.38 ± 0.04 0.04 ± 0.01 0.04 ± 0.01 0.28 ± 0.07 0.07 ± 0.01
Values are given as mean ± SE.
VPDH, the flux through pyruvate dehydrogenase; Vx, the exchange rate between the mitochondrial TCA cycle intermediate 2-oxoglutarate and the
cytosolic amino acid glutamate; CMRglc(ox), the rate of oxidative glucose consumption; VNT, the apparent rate of glutamatergic neurotransmission;
VPC, the rate of pyruvate carboxylase; Vg, the glial TCA cycle flux; Vsyn, the flux through glutamine synthetase.
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where brain glucose transport under these conditions was
not assessed. That study stated that cerebral metabolism
in coma (a pentobarbital dose of 40 to 60 mg · kg−1 · h−1
intraperitoneally) was depressed to 10% of the basal me-
tabolism. The study further reported that most of the
cerebral oxidative glucose consumption rate was coupled
in a 1:1 stoichiometric fashion to glutamatergic action.
According to previous measurements of brain glucose
content as a function of plasma glucose content in the
awake rat (Mason et al., 1992) and the proposed 10-fold
reduction in metabolism in coma (Sibson et al., 1998),
brain glucose concentrations should rise to values close
to the plasma glucose concentration according to the na-
ture of the glucose transport process by facilitated diffu-
sion. Our analysis of the glucose transport kinetics, how-
ever, is consistent with only a twofold reduction in the
metabolic rate.
These findings shed light on the interpretation of “stoi-
chiometric coupling of brain glucose metabolism and
glutamatergic neuronal activity” (Sibson et al., 1998),
which was recently challenged based on data obtained in
the conscious human brain where glial and neuronal me-
tabolism was simultaneously assessed (Gruetter et al.,
2001). In the study by Sibson et al. and more recent
reviews of that paper (Shulman and Rothman, 2001), it
was suggested that the total oxidative glucose consump-
tion in the brain is linearly correlated with glutamatergic
action with a 1:1 stoichiometry. Energy metabolism in
the glial compartment under deep pentobarbital anesthe-
sia, however, was not assessed in that study, and neither
was the glutamate-glutamine cycle (represented by VNT
in our modeling); instead it was assumed to be zero at
isoelectricity. Last, a further limitation of that study was
that the turnover of only 13Glu4(t) and 13Gln4(t) was
measured, which did not permit the measurement of Vx.
Instead, that study was based on an assumed Vx of ap-
proximately 50 mol · g−1 · min−1 (Mason et al., 1992).
However, it is not clear to what extent the previous study
by Mason et al. represents normal physiology, since data
obtained from paralyzed, awake rats following trache-
otomy and scalp retraction were used. In contrast, the
present study reports a Vx of 0.35 mol · g−1 · min−1, our
previous study in awake humans reported 0.58
mol · g−1 · min−1, and a recent study in -chloralose
anesthetized rats reported 0.9 mol · g−1 · min−1 (Henry
et al., 2002). In all studies of normal, anesthetized rats or
humans, Vx was on the order of VPDH, which is strong
supporting evidence that the malate-aspartate shuttle can
be measured by 13C NMR in the brain and that it is a
major flux-controlling mechanism.
Our studies suggest that the energy required for glu-
tamate signaling is very low. In the present study, the
to t a l ATP consumpt ion i s e s t ima ted a t 10
mol · g−1 · min−1, of which approximately VNT × 2.25
0.1 mol · g−1 · min−1 is devoted to the restoration of the
ion concentration following glutamate uptake into astro-
cytes and conversion of the glutamate to glutamine and
then export back to neurons. This amounts to glutamate
signaling requiring less than 2% of the glial (or neuronal)
energy consumed under deep anesthesia, where electrical
activity is greatly or even completely depressed. A calcu-
lation of the ATP synthesis required for glutamate cycling
from our previous study (Gruetter et al., 2001) indicated
that approximately 3% of total ATP is devoted to that task
in the conscious human brain. These calculations are in
excellent agreement with recent theoretical considerations
(Attwell and Laughlin, 2001).
Because the present results with the more complete
modeling and more extensive analysis of cerebral energy
metabolism suggest that there is considerable oxidative
ATP synthesis in glia and that cerebral glucose consump-
tion is still substantial under deep pentobarbital anesthe-
sia, the “molar stoichiometric coupling of total glucose
consumption with neuronal glutamate release” (Sibson et
al., 1998) hardly exists. It was also suggested in our
previous study (Gruetter et al., 2001) that there is poten-
tially a correlation between neuronal glutamate release,
VNT, and the TCA cycle rate in neurons, VPDH. How-
ever, a correlation between VNT, reflecting the glial en-
ergy demands of glutamate recycling, and VPDH, repre-
senting neuronal energy metabolism, eliminates the
chemical basis for the proposed molar stoichiometry be-
tween glucose metabolism and glutamatergic action.
Therefore, in light of these results, the findings by Sibson
et al. require reinterpretation and additional work is
needed. Based on the present results in the deeply anes-
thetized rat brain and our recent results in the conscious
human brain (Gruetter et al., 2001), we offer the follow-
ing interpretation: there is undoubtedly a coupling be-
tween glutamatergic action and glial energy metabolism,
as suggested by the increased deoxyglucose uptake with
increasing extracellular glutamate concentration (Magis-
tretti et al., 1993) and increased oxygen consumption
(Eriksson et al., 1995). The precise relation between
changes in neurotransmission rates and energy metabo-
lism, however, has not yet been satisfactorily established.
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